• PARDOPRUNOX chembl:CHEMBL2103832

    Alternate Names:

    SLV-308
    PARDOPRUNOX
    SLV308
    DU-126891

    Drug Info:

    FDA Approval not approved
    Drug Class small molecule
    Drug Indications antiparkinson agent
    (0 More Sources)

    Publications:

  • Interaction Score: 0.21

    Interaction Types & Directionality:
    partial agonist (activating)

    Interaction Info:
    Trial Name pardoprunox, SLV 308
    Novel drug target Established target
    Mechanism of Interaction Dopamine receptors; D2 & D3 partial agonist

    PMIDs:
    None found


  • Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name pardoprunox, SLV 308
    Novel drug target Established target

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial

  • Interaction Score: 0.17

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Mechanism of Interaction Serotonin 1a (5-HT1a) receptor agonist
    Direct Interaction yes
    Trial Name pardoprunox, SLV 308

    PMIDs:
    None found


  • Interaction Score: 0.15

    Interaction Types & Directionality:
    partial agonist (activating)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Dopamine receptors; D2 & D3 partial agonist
    Trial Name pardoprunox, SLV 308

    PMIDs:
    None found


  • Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name pardoprunox, SLV 308
    Novel drug target Established target

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial

  • Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name pardoprunox, SLV 308
    Novel drug target Established target

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial

  • Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name pardoprunox, SLV 308
    Novel drug target Established target

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial